Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains by unknown
Expression Cloning of a Human Granulocyte
Colony-stimulating Factor Receptor: A Structural
Mosaic of Hematopoietin Receptor, Immunoglobulin,
and Fibronectin Domains
By Alf Larsen, Terri Davis, Benson M. Curtis, Steve Gimpel,
John E. Sims, David Cosman, Linda Park, Eric Sorensen,
Carl J. March, and Craig A. Smith
From the Immunex Corporation, Seatth Washington 98101
Summary
We report the isolation from a placental library, of two cDNAs that can encode high affinity
receptors for granulocyte colony-stimulating factor (GCSF) when expressed in COS-7 cells. The
cDNAs are predicted to encode integral membrane proteins of759 and 812 amino acids in length.
The predicted extracellular and membrane spanning sequences of the two clones are identical,
as are the first 96 amino acids of their respective cytoplasmic regions. Different COOH termini
of 34 or 87 residues are predicted for the two cDNAs, due apparently to alternate splicing. The
receptor with the longer cytoplasmic domain is the closest human homologue of the murine
G-CSF receptor recently described by Fukunaga et al. (Fukunaga, R., E. Ishizaka-Ikeda, Y Seto,
and S. Nagata. 1990. Cell. 61:341). A hybridization probe derived from the placental G-CSF
receptor cDNA detects a N3-kb transcript in RNAs isolated from placenta and a number of
lymphoid and myeloid cells. The extracellular region of the G-CSF receptors is composed of
four distinct types of structural domains, previously recognized in other cell surface proteins.
In addition to the two domains of the HP receptor family-defining region (Patthy, L. 1990.
Cell. 61:13) it incorporates one NH2-terminal Ig-like domain, and three additional repeats of
fibronectin type III-like domains. The presence of both an NH2-terminal Ig-like domain and
multiple membrane-proximal FN3-like domains suggests that the GCSF receptor maybe derived
from an ancestral NCAM-like molecule and that the GCSF receptor may function in some adhesion
or recognition events at the cell surface in addition to the binding of G-CSF.
G
ranulocyte colony-stimulating factor (G-CSF)i is a gly-
coprotein secreted by macrophages, fibroblasts, and en-
dothelial cells originally identified by its ability to stimulate
the survival, proliferation, and differentiation in vitro ofpre-
dominantly neutrophilic granulocytes from bone marrow pro-
genitors (1). The capacity of G-CSF to regulate in vivo
granulopoiesis is supported by animal and clinical studies,
which demonstrated a reversible rise in circulating neutro-
phil levels in response to administered recombinant G-CSF
(2). G-CSF has pleiotropic effects on mature neutrophils, en-
hancing their survival and stimulating functional activation,
including induction of neutrophil alkaline phosphatase (3)
and high affinity IgA Fc receptors (4), priming for respira-
tory burst (5, 6), and increased chemotaxis (7). G-CSF effects
1 Abbreviations used in thispaper: FN3, fibmnectin type III homology unit;
GCSF, granulocyte colony-stimulating factor; HP receptor, hematopoietin
receptor; NCAM, neural cell adhesion molecule; PRL, prolactin.
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have also been observed on hernatopoietic cells that are not
committed to the granulocyte lineage, for example, stimula-
tion of the proliferation or monocytic differentiation in vitro
of some myeloid leukemic cells (8-10) and, in synergy with
other colony-stimulating factors, the proliferation in vitro of
some multipotential hernatopoietic precursors (11-13). A re-
cent clinical study implicates G-CSF in the regulation of
humanerythropoiesis (14). GCSF may also affect nonhemato-
poietic cells, since it appears to stimulate the proliferation
and migration of endothelial cells (15), and the growth of
cell linesderived from colon adenocarcinomas (16) and small
cell lung carcinomas (17).
These diverse effects of G-CSF are mediated by the inter-
action of G-CSF and specific cell surface receptors. Initial
binding studies with native murine G-CSF detected low
numbers of receptors on responsive murine cell lines and
human bone marrow cells ofthe neutrophilic lineage (18-20).
Affinity crosslinking studies suggested a murine receptor mo-
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improved stability have been shown to bind a single class of
sites (Kd = 100-500 pM) on circulating neutrophils (22),
U937 cells (23), placental membranes, and trophoblasts (24).
Similar affinities have been measured for the binding of na-
tive G-CSF to asingle classof sites on myeloidleukemic and
small cell lung carcinoma cell lines (17). Although affinity
crosslinking experiments detected human receptors of M,
-150,000 on neutrophils, an additional crosslink to a protein
of M r -120,000 couldbe detected on placental membranes,
suggesting a more complex receptor composition (22, 24).
Here we report the isolation from a placental library of
two cDNA clones that encode high affinity receptors for
G-CSF when expressedin COS-7 cells. Thetwoclones encode
identicalextracellular and transmembrane sequences, butdiffer
in theCOOH-terminal portion oftheir cytoplasmic regions,
due to what appears to be alternate splicing. The predicted
protein sequence ofone clone suggests it is the strict human
homologue of a recently cloned murine G-CSF receptor
cDNA (25) .
Materials and Methods
Human G-CSFPreparation.
￿
HumanG-CSF (26) wasexpressed
in yeast, using the a-factor secretion system (27), as a mutein in
which Cys17 was replaced by serine and Arg22, by lysine. These
alterations inhibit, respectively, the formation of disulfide-linked
oligomers and inappropriate processing through destruction of a
I{exII recognition site. Alternatively, a fusion polypeptide of the
same constructbutincorporating a hydrophilic octapeptide at the
NHa terminus to aid in purification (28) was also expressed. The
biological activities of both purified forms were -2 x 10' U/mg
determined in a standard proliferation assayusingthemurine my-
eloid leukemic cell line DA1. 1 U corresponds to that amount of
G-CSF that gives half-maximal [3H]TdR incorporation.
Radiolabeling of G-CSF.
￿
Purified human G-CSF was radiola-
beled to a specific activity of 7 x 10" cpm/mmol using a solid-
phase chloramineT analogue. 5 p,g of purified G-CSF and 2 P,Ci
Na""I in 150 pl PBS was placed in a 10 x 75 mm glass tube pre-
viously coated with 5i~g of Iodogen (Pierce Chemical Co., Rock-
ford, IL) and incubated for 25 min, 4°C. Free and ligand-bound
iodine were subsequently separatedby gelfiltration through a 1 ml
column of Biogel P-6 (BioRadLaboratories, Richmond, CA) that
had been blocked with BSA. Radiolabeled stocks were stored at
4°C in RPMI-1640containing 2.5% BSA, 20 mM Hepes buffer,
and 0.2% sodium azide, pH 7.2 (binding medium). The specific
radioactivities of labeled G-CSF were based on determination of
initial protein concentration by amino acid analysis, with correc-
tion from control experiments to determineprotein recovery after
iodination, in which an aliquot of G-CSFwas mixedwith ".I-G-
CSF and the iodination protocol repeated, with omission of
Na".'I.
Cell Lines and Tissue Preparations.
￿
HL60, U937, C10, KG-1,
HeLa, RAJI, MJ, and RPMI 1788 cell lines were maintained in
RPMI 1640 (Gibco Laboratories, Grand Island, NY), 10% FCS,
2 mM glutamine, and 50 p,M 2-ME at 37°C in a humidified at-
mosphere of 5% COz in air. Peripheral blood granulocytes were
isolated by sedimentationon discontinuousFicoll Hypaque(Sigma
Chemical Co., St. Louis, MO)gradientsfollowed by redbloodcell
lysis in ammonium chloride. Placental membranes were isolated
as follows. Fresh, full-termhumanplacenta, obtained from Swedish
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Hospital Medical Center (Seattle, WA) on ice, were washed six
times with ice-cold PBS to extract excess blood, and the tissue,
trimmed of amnion and chorion, was cut into small pieces. The
pieces were transferred to onevolume of Buffer A(30mM Hepes,
pH 7.4, containing 0.25 M sucrose, 1 mM PMSF, 1 PM pepstatin
A, 10 gM leupeptin, 2 mM o-phenanthroline, and 0.02 U/ml
aprotinin), homogenized for five 1-min intervals with a PT10/35
homogenizer (Brinkman, Westbury NY) at setting 7 and cen-
trifuged at 6,800g for 30 min, 4°C. The supernatant was made
0.1 Min sodium chloride and 0.2 mM in magnesiumchloride and
centrifuged at 42,000 g for 40 min at 4°C. The resulting pellets
were washed twicein Buffer Aby resuspension andcentrifugation
as above. The final sedimented membraneswere resuspended in 30
ml of Buffer A at a protein concentration of 10-20 mg/ml and
stored at -70°C.
Binding Assays andData Analysis.
￿
Forequilibrium bindingassays
with native (placental membrane) G-CSFreceptor, serial dilutions
of 12'1-G-CSF in binding media were incubated with 300 pg
membrane (protein) in 10 x 75 mm glass tubes in a total volume
of 100 P.1 for2 h, 4°C. Controlexperiments showed equilibration
hadbeen reachedin this time. Boundligand was measured by sub-
sequent collection of membranes in the reaction mixture on glass
microfiber filters(Whatman, Hillsboro, OR)usinga vacuum filtra-
tion apparatus. Filters were washed three times with ice-cold
PBS/BSA (1 mg/ml) before gamma counting. Nonspecific binding
was determined foreach data pointwith acontrol tube containing
a400-fold molarexcess ofunlabeled GCSF. Free radiolabeled ligand
foreach data point was measured by counting an aliquot ofligand
identically incubated in the absence of membranes, after subtrac-
tion ofthecorresponding boundcounts. Bindingcurves were plotted
in theScatchardcoordinate system, expressing boundligand in units
of fmole/milligram membrane protein.
Forequilibrium bindingassays with recombinant G-CSF receptor,
COS-7cellstransfected with either theD-7or 25-1 GCSF receptor
cDNA clone (COS-G-CSFr) were first diluted 10-fold with carrier
cells (EL4-3 * murine T cells) to prevent COS cell aggregation.
EL4-3* and untransfected COS cells were both shown to lack
receptors for human G-CSF. Serial dilutions of "'I-G-CSF in
binding media were incubated with cells (2 x 106 total cells/ml)
for2 h at 4°Cin a total volume of 150pl using96-wellmicrotiter
plates. Free andbound ligand were separatedby centrifugation of
duplicate 60-Ftl aliquots of the reaction mixture in plastic tubes
containing a phthalate oil mixture (29). The tubes were cut, and
supernatant (free ligand) and pellets (bound ligand) were gamma
counted. Nonspecific bindingwasdetermined by inclusionofa200-
fold molar excess of unlabeled G-CSF in the reaction mixture at
one ligand dilution; the linearly extrapolated nonspecific binding
was subtracted from each data point to generate specific binding.
Bindingparameters determined on adherent COS-G-CSFreceptor
cells were similar to those determined in the suspension assay.
Affinity Cross-linking.
￿
Adherent COS cells on 10-cm culture
dishes transiently expressing therecombinant G-CSF receptorwere
incubated with "II-G-CSF (1 nM) in RPMI 1640 for 2 h at 4°C
in the presence or absence ofunlabeledG-CSF (11AM) . Cellswere
washed twice in ice-cold PBS and then crosslinked in situ with
0.1 mg/ml bis-(sulfosuccinimidyl) suberate (BS3, Pierce Chemical
Co.) in PBS at 25°C for 30 min. Cells were subsequently washed
twicewith PBS andthen lysedwith 0.5 mlof PBS/1% Triton con-
taining protease inhibitors (2 mM PMSF, 10 tzM pepstatin A, 10
uM leupeptin, 2 mM o-phenanthroline, 2 mM EGTA, 1.25 mM
benzamidine, 0.5 mM EDTA, and2wg/mlsoybean trypsin inhib-
itor). Lysates were scraped from plates, microfuged at 12,000gfor
10 min, and supernatants retained. Placental membranes(8 mg pro-
Cloning of a Human Granulocyte Colony-stimulating Factor Receptortein/ml) were incubated in 1.5-ml plastic microfuge tubes with
1 mM 12'I-G-CSF in a total volume of 100 AI PBS for 2 h at 4°C
in the presence or absence of unlabeled G-CSF (1 AM). Membranes
were then washed two times with ice cold PBS, resuspended in
100 Al of PBS, and incubated with BS' (0.1 mg/ml) for 30 min
at 25°C. Membranes were washed twice, then lysed in 150 Al of
PBS 1% Triton (with protease inhibitors) for 30 min at 4°C.
Insoluble debris was removed by centrifugation for 30 min at
10,000 g, and the supernatant was retained.
SDS-PAGE.
￿
Samples, including methyl 1°C-labeled molecular
weight markers (Bethesda Research Laboratories, Bethesda, MD),
were boiled for 30 min in sample buffer (0.06 M Tris-HCI, pH
6 .8, 2% SDS, 10% glycerol, 5% 2-ME) and analyzed on an 8%
SDS gel (30). After electrophoresis, gels were fixed in 25%
isopropanol, 10% acetic acid, dried, and autoradiographed with
Kodak X-Omat AR film at -70°C.
cDNA Library Construction and Screening.
￿
Total cell RNA was
isolated from whole fresh placental tissue as described below and
polyadenylated RNAprepared bychromatography on oligo(dT)-cel-
lulose as described (31). Double-stranded, ohgo(dT)-primed cDNA
was prepared with a commercial kit (Amersham Corp., Arlington
Heights, IL). The resulting cDNA was size fractionated by chro-
matography on Sephacryl S-1000 (Pharmacia Fine Chemicals, Pis-
cataway, NJ) in 0.5 M sodium acetate. The excluded cDNA was
cloned into the Bg1II site of the mammalian expression vector,
pDC302 (32) by an adaptor method similar to that described by
Haymerle et al. (33). Briefly, noncomplementary ofgonucleotides
ofthe sequence 5'-GATCTTGGAACGAGACGACCTGCT and 5'-
AGCAGGTCGTCTCGTTCCAA synthesized on a DNA syn-
thesizer (model 380A; Applied Biosystems, Foster City, CA) were
annealed and ligated in separate reactions to either cDNA or Bg1II
cut vector. Nonligated oligonucleotides were separated from cDNA
or vectorby chromatography over Sepharose CL2B (Pharmacia Fine
Chemicals) at 65°C in 10 mM Tris (pH 8.0), 0.1 mM EDTA. 5 ng
ofadaptored vector was (gated to adaptored cDNA in 10-Al reac-
tions containing 50 mM sodium chloride, 50 rnM Tris-HCl (pH
7.5), 10 mM magnesium chloride, 1 mM spermidine, 0.5 mM ATP,
0.1 U/pl T4 polynucleotide kinase and 0.4 U//al T4 DNA ligase
for 30 min at 37°C. Reactions were then desalted by drop dialysis
on VSWP 013 filters (Millipore Corp., Bedford, MA) against dis-
tilled water for 40 min immediately before electroporation into Esch-
erichia coli strain DH5 a as described (34). Transformants were ob-
tained with an average cDNA insert size of 1.6 kb. Pools of 600
colonies were prepared and DNA minipreps of these were trans-
fected into COS cells as described (35). After 3 d growth in
DME/10% FCS, the cells were screened for 115I-G-CSF binding
by an in situ autoradiographic plate binding assay (36).
RNA Analysis. Total cellular RNAs were isolated by the
guanidinium isothiocyanate-cesium chloride method and electro-
phoresed through formaldehyde agarose gels as described (31). RNA
was transferred to nylon filters (Amersham) by capillary blotting
and UV crosslinked using a Stratalinker (Stratagene, LaJolla, CA).
Filters were probed with a 31P-labeled antisense RNA prepared by
T7 RNA polymerase transcription of a subclone of the D7 cDNA
in pB1ueSK (Stratagene). High stringency blot hybridization and
washing conditions were as previously described (35).
Sequence Analysis.
￿
Sequences were aligned using various com-
puter programs (GAP; 37, 38) and the progressive alignment method
of Feng and Doolittle (39) as well as by visual inspection. With
the exception of the alignment between the human and murine
G-CSF receptors, a consensus alignment was generated for all se-
quences, rather than optimizing the alignment between any given
pairof sequences. Alignment scores were generated using the NBRF
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program ALIGN using the NO data matrix with a bias of +6
and a gap penalty of 6. The prediction of residues involved in
a-strands in immunoglobulin domain folding patterns used the turn
and secondary structure prediction algorithms ofCohen et al. (40),
the hydrophobic moment algorithm ofEisenberg et al. (41) as well
as by inspection.
Results
Isolation ofHuman G-CSFReceptor cDNAs.
￿
Quantitative
binding studies using radioiodinated G-CSF on a panel of
human cell lines demonstrated low level expression of a single
class of binding sites (N <1,000/cell, Ka -1 nM; data not
shown). G-CSF receptors with a similar affinity were detected
on placental membranes (see below), but at a level of -200
fmol/mg. Since binding of epidermal growth factor to A431
cell membranes at this levelwould correspondto a site number
of-106/cell (42) we concluded that G-CSF receptors were
expressed at unusually high levels in placental tissue. A placental
cDNA librarywas prepared in a mammalian expression vector
and DNA from pools of -600 transformants were transfected
into COS cell that were then screened for 1211-G-CSF binding
by contact autoradiography (37). A positive clone, D7, was
obtained after screening 20 pools and contained a 2.6-kb cDNA
insert that was used as a hybridization probe to identify three
additional related clones from the same library Restriction
digests and DNA sequencing showed that the cDNA clones
fell into two classes: three were of the D7 type and one of
a somewhat different form, 25-1, shown in Fig. 1. The 25-1
clone differs from the D7 clones only in its lack of a poly(A)
tract and in the presence of a 419-bp internal sequence insert.
This insert occurs between nt 2411 and 2412 of the D7 cDNA
and appears to be derived from an unspliced intron since it
contains splice donor and acceptor consensus sequences at
the junctions with the D7 sequence.
DNA sequencingof these clones showed that the first ATG
occurs in a context corresponding well to the Kozak con-
sensus sequence (CCA/GCCATG; 43) and initiates a reading
frame that terminates after 11 codons. The next potential ini-
tiation codon occurs 45 nt downstream, within an inferior
Kozak context. This reading frame encodes proteins of 783
and 836 amino acids in the D7 and 25-1 cDNAs, respectively.
Hydropathy analysis identifiedtwo major hydrophobic regions
in the sequence (Fig. 1 D). The first, at the NH2 terminus,
is a presumed hydrophobic signal sequence of 24 residues;
the second, between residues 604 and 629, is a presumed trans-
membrane domain that makes a single helical span (Fig. 1
B). Both forms ofreceptor are thus composed ofan extracel-
lularregion of 603 amino acids and a transmembrane region
of26 amino acids, but differ in the predicted COOH-terminal
portions of their cytoplasmic domains. The protein encoded
by cDNA D7 has a cytoplasmic domain of 130 amino acids,
while the unspliced intron sequence inserted in clone 25-1
after amino acid 725 predicts a cytoplasmic domain of 183
residues. The COOH-terminal amino acid sequence of D7
appears significantly more hydrophobic than that of 25-1 and
contains one less Cys residue (Fig. 1). Both the D7 and 25-1
cytoplasmic sequences have high contents ofproline (14.6 andA35 D-7
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Figure 1 . Human G-CSF receptor
cDNAs. (A) Schematic representation
and restriction map ofGCSF receptor
cDNAclones D7 and 25-1. Restriction
sites are indicated for BamHl (B) and
Sstl (S). The solid arrow marks the po-
sition in the D7 sequence at which the
25-1-specific insertion occurs. The in-
sert sequence present only in the 25-1
clone is indicated as a filledbar, allother
sequence is identical in the two clones.
The deduced coding sequences are
shown as as wide bars, noncoding se-
quences as narrow bars. The predicted
signal transfer and transmembrane se-
quences are shown crosshatched. The
35-residue poly(A) tail of the D7 clone
is shown as A35. (B) The nucleotide
and deduced amino acid sequence of
clone D7. The signal peptide cleavage
site predictedby the probability weight
matrix of von Heijne (75) is shown by
an open arrow, and the predicted NH2
terminus ofthe mature protein is desig-
nated residue 1. The predicted mem-
brane spanning sequence is indicated by
heavy underline and the Trp-Ser motif
by a light underline. Cysteine residues
are boxed and potential Winked gly-
cosylation sites are indicatedby asterisks.
The position of the 25-1 intron inser-
tion point is indicated by a solid arrow.
(C) The nucleotide and deduced amino
acidsequenceof the3' end ofclone 25-1.
Enumeration is continuous with B.
Cysteine residues are boxed. Solid
arrows indicate the junctions of the
419-bp insert with sequences common
toboth 25-1 andD7. (D) Onfacingpage
Hydropathicity plot oftheD7 and 25-1
receptor sequence according to the
methodofKyte andDoolittle (76). The
predicted signal and membrane-span-
rung sequences are indicatedby arrows.
These sequence data are available from
EMBL/Genbank/DDJB under the ac-
cessionnumbers X55720(clone 137) and
X55721 (clone 25-1).
1515 CCC CCC AAT CCA TOG CCr CAo GGC TAT GTa Art GAG Too GGC CM GGC CCC CCC AGC GM AGC AAT AG: AhC AAG ACC TGG AGG ATG Gu. 1604
427 Pro Pro Ash Pro Trp Pro Gin Gly Tyr Val Ile Glu Try, Gly Iwa Gly Pro Pro SK Ala SK Ash See Ash Lys The Trp Arg Hot Glu 456
1605 CAG AAT GGG AGA GCC MG GGG We CTG CrG AAG GAG AAC ATC AGG CCC T1T CAG CIC TAT GAG ATC ATC GIG ACT CCC TTG TAC CAG GAC
457 Gin Ann Gly Arg Ala The Gly Phe Lou Lu Lys Olu Ash Ile Arg Pro Pha Gin Lu Tyr Glu Ile Ile Val The Pro LAU Tyr Gin top
1694
466
1695 ACC ATG .GGA CCC TCC CAG CAT OTC TAT GCC TK TCT CAA GM An GCT CCC TCC CAT GCC CCA GAG CTG CAT CIA AAG CAC ATT GGC AM
487 The Met Gly Pro Sar Gin His Val Tyr Ala Tyr See Gin Glu Met Ala Pro See His Ala Pro Glu Lu His Lou Lys His Ile Gly Lys
1784
516
1785 ACC TGO GCA CAG CTG GAG TOO GTG CCT GAG CCC CCT GIG CTG GGG 1VA AGC CCC Crr ACC CAC TAC ACC ATC TTC TOG ACC AAC GCT CM.. 1874
517 The Trp Ala Gin Lau Glu Trp Val Pro Glu Pea Pro Glu Lu Gly Lys See Pro Lu The His Tyr The Ile Phe Trp The Aan Ala Gin 546
1875 MC CM KC TK TCC CCC AK C1O NS GCC TCC KC CGT GGC 1IT GTC CTC CAS GGC CTG GAG CCC GCC AGT CTG TAT CAC AMC CAC CK 1964
547 Mn Gin See Phe Sat Ala Ile
Lou
Mn Alt See SK Arg Gly Phe Val LOU His Gly Lu Glu Pro Ala See Lou Tyr His Ile His Lu 576
s
1964 ATO GCI GCC MC CM CCT GCA GCC ACC MC MT ACA GTC CT'C ACC C1G ATG ACC TTG ACC CG GM GCA TCG GAG CIA CAC ATC AK CIO 2054
577 Hot Ala Ala See Gin Ala Gly Ala The Am See The Val Lou The Lau Met The Lou The Pro Glu Gly See
Glu Lu His Ile 110 LOU 606
2055 GGC CTG TTC GGC CTC C1r CTG TM CIC ACC TGC CTC TGT GGA ACT OCC TGG CTC TOT TGC AGC CCC AAC AGO A G MT CCC CrC TGG CCA 2144
607 Gly Lau Phe Gly Lu Lau LOU Lau Lu USMLu Cya Gly The Ala Trp . Lau S C Sat Pro Ash Arg Lys Asn Pro Lou Trp Pro 636
2145 AOr GK CCA GAC CCA OCT CAC ACC AGC CM 0GC TCC TOG M CCC MA ATC M GAG GAG GAT GCC Trc CAG CIG CCC GGC C1T GGC ACO 2234
637 See Val Pro Asp Pro Ala His See See Ian Gly See Trp Val Pro The 119 Hot Glu Glu Asp Ala Phe Gln Lou Pro Gly Lu Gly The 666
2235 CCA CCC ATC ACC AA6 CrC ACA PTO CTG GAG fd4 aAT OM AAG AAG CCV GTO'CCG TOG GAG TCC CAT AAC AGC ICA GAG ACC TOT GGC CrC 2324
661 Pro Pro Ile The Lys Lu The Val Lu Glu Gin Asp Glu Lye Lys Pro Val Pro Tep Glu Ser His Ash See See GI, Thr CTs Gly Lu 696
2325 CCC ACT CTG GTC CAG ACC TAT GIG CPC CAG OOO GAC CCh AGA GCh = I= ACC CAG CCC CM TCC CAG TCr GGC ACC AGC GAT CAGv GCT 2414
697 Pro The EAU Val Gin The Tyr Val Lau Gin Gly Asp Pro Arq Ala Val See
The Gin Pro Gin Sar Gin see Gly The See Asp Gin Ala 726
2415 GGG CCr C CC AGG CGh TCr GCA TAC TrT AM CAC CAG ATC ATG CTC CAT CCA GCC CCA CCC ANT CAC Crr TTG TGC TIG TIT CCr ATA MT 2504
727 Gly Pro Pro Arg Arg See Ala Tyr Phe Lys Asp Gln Ile Met Lu His Pro Ala Pro Pro Ma Gly Lu LaurZV,7I.eu Phe Pro Ile The 756
2505 TCA GTA TTG TM ACT AOT ITT TOG TIT WA AAA AM AAA AAA 2546
757 See Val f.ou end 770
2409 CAG GK CIT TAT GOO CAG CIG QG GGC AGC CCC ACA AGC CCA C40 CCJ1 GGG CAC TAT CPC CG< IGT GAC TCC ACT CAG CCC CTC TTG GCG 2498
725 Gin Val Lu Tyr Gly Gin tau Lu Gly Set Pro The See Pro Gly Pro Gly His Tyr Lu ArgEE Asp See The Gin Pro Lu Lou Ala 754
2499 GGC CTC ACC CCC AGC CCC AAG TCC TAT GM MC C1C TOG TIC CAG GCC AGC CCC TIG GGG ACC CM GTA ACC CCA GCC CCA AGC CIG GAG 2588
155 Gly Lu The Pro Sac Pro Lys See Tyr Glu Ash LAU Try Phe Gin Ala See Pro Lu Gly The Lou Val The Pro Ala Pro Ser Gin GI, 184
2569 GAC GAC TGT GK Trr OGG C CA CM CTC AhC TIC CCC CrC CTG CAA OW Arc CGG OTC ChT GOG ATG GAG GCG C7G GGG A4C TTC TAG GGC
785 Asp _p r67sJ Val Phe Gly Pro Lou Iwu Ash Phe Pro I.eu Lau Gin Gly 110 Arg Val His Gly Hat Glu Ala Lu Gly See Phe end
2678
614
2679 TTC Cl'G GGG TTC CCT TCT TOG GCC TGC Crr TTA AAG GCC TGA GCT AGC TOO AGA M .A GGG GAG WT CCA TM GCC CAT GAC TM AM CIA
2769 CCC CAG CCC AGG CTC ICA CCA TCr CCA OK ACC AGC ATC TCC CrC TCC TCC CAA TCT CU TAG VGCT GGG CCT CCC AGG CGA TCT GCA TAC
2659 TTT AM . GAC CAG ATC ATG CTC CAT CCA GCC CCA CCC AAT GGC CTT TTG TGC TTG Trr CCT ATA ACT ICA GTA 1T 2932
2768
2858
75
TG GAC TGC MC TOG TTT CM GAA CTr CTC TTG MG AGA AGA GAG ACC AW GaZ GCC AAG CAG GGG Cr0 WC CAG
AGG TGC CM CAT GGG GM ACT GAG GCS COG CTC GGh AAG GTG AM TM CTr OTC CAA GAT CAC AAA GCT GCT GAA CAT CAA GTT GGT GCT
14
164
a
34S
37
ATT CIO TGG AGA CIG GGA GCA GAG CrT CJIG CCC GGG GOC AGO CNl CAG COT CM TCr CAS GGG ACC CM GAA TCT ATC ATC ACC CTG CCC
Ile Leu Trp Keg Lou Gly Ala Glu Lu Gin Pro Gly Gly Arg Gin Gin Arg Lu See Asp Gly The Gin Glu Ser Ile Ile The Lu Pro
434
66
435
67
CAC CPC NS CAC MT OA WC 37I C1C KC CM MC 1OG GGC NS M .C CiG CM AK CLG GM CM GTT GAG CTG CGC GG G,C His
Lu Asn His The Gin Ala Phe Lou Sac Cya
GTN
Cya LAu Asa Trp Gly Ash See Lou Gin Ile LAU Asp Gin Val Glu IAU Arg Ala Gly
524
96
525
91
TAC CCT CCA GCC AMA CCC CAC AAC CrC TCC TOC CK MG MC CTC ACA ACC AGC AOC QC ATC TGC CAG TCA GAG CCA GGA CCr GAG ACC
Tyr Pro Pro Ala 119 Pro His Ash Lu Ser Cys Lou Mat Ash Lou The The Sac Sac Lu 11. Cys Gin Trp Glu Pro Gly Pro Glu The
614
126
615
127
CAC CIA CCC ACC ACC TIC ALT CIO AAa wr TIC ASO Aae 000 GGC AAC TGT CAG ACC CAA GOO GAC TCC ATC CrG GAC TGC GTa CCC AAG
His Lou Pro The So, Pha The LaU !ya Sat Phe Lys So, keg Gly Asn cps Gln The Gin Gly Asp See Ile Iru Asp Cys val Pro Lys
704
156
705
157
GAC GW CAG AGC CAC TGC TGC ATC CCA COC MA CAC CTG CTO M TAC CAG MT AM GGC ATC TOG GTG CAG GCA GAG MT GCG CIG GGG
Asp Gly Oln So, His Lys Cys Ile Pro Mg Lys His tau Lu TAU Tyr Gin Ash Not Gly Ile Trp Val Gin Ala Glu Ash Ala Lu Gly
794
186
795
187
ACC MC ATG TCC CCA CM CTO TOP CTT OAT CCC ATG W GTT GIG MA CrG GAG CCC CCC ATG CrG OW ACC ATG GAC CCC AGC CCT GAA
The See Hat Sae Pro Gin leuOLa Asp Pro Hat by Val Val Lys Lou Glu Pro Pro Hat Lu Arg The Hot Asp Pro Set Pro Glu
589
216
885
211
GCG OCC CCr CCC CAG OG GGC TGC LTA CAG CIO TOC TOO GM CCh TGG ChO CCA CAC CM CAC ATA AAT CAG AM TGT GAG CIG OGC CAC
Ala Ala Pro Pro Gin Ala Gly Cyt Lu Gin Lu Cys Trp Glu Pro Trp Gin Pro Gly Lou His Ile Ash Gin Lys Cys Glu Lu Arg His
974
246
915
247
AAG CCG CAG CGT GW GAA GCC AGC TOO WA CTG OW GGC CCC CrC CCC TTG GAG GCC CTr CAG TAT GAG CTC TGC GGG CTC CrC CCA GCC
Lys Pro Oln Arg Gly Glu Ala SK Trp Ala Lu Val Gly Pro Lu Pre Lou Glu Ala Lu Gin Tyr Glu LuQGly Lu EAU Pro Ala
1064
276
1065
277
ACG OCC TAC ACC CIO CAG ATA CGC TGC ATC CGC TGG CCC CTG CCT GOC CAC TGO AGC GAC TOG AGC CCC AGC CrG GIG CM ACA ACT ACC
The Ala Tyr The Lou Gin Ile ArlO lla Arg Trp Pro Leu Pro Gly His Trp See by Trp See Pro Sar Lou Glu Lu Arg The The
1154
306
301 Glu Arg Ala Pro The Val Arg Lou Asp The Trp Trp Arg Gin Arg Gin- Lu Asp Pro Arg The Val Gin Lu Pha Trp Lys Pro Val Pro 336
1
245
337
QG GAG GM GK MC GGA COG ATC CAA GOT TAT ON GM TCT TGO AGA CM TCA GOC CAG GCr GGG GCC ATC CrG CCC CTC TGC AAC ACC
Lau Glu Glu Asp Sae Gly Arg Ile Gin Gly Tyr Val Val Sar Trp Arg Pro Sae Gly Gin Ala Gly Ala Ile Lou Pro LauOAen The
1334
366
1335 ACA GM . CrC AGC TGC ACC TIC Ch[ CIO CCr TCA GM OCC Cho am GIG GCC CTT GIG GCC TAT AAC ICA GCC GGG ACC TCT CGC CCC ACC 1424
367 The Glu
Lou
Ser[C" . The Phe His Lu Pro Sar Glu Ala Gin Glu Val Ala Lou Val Ala Tyr Ash See Ala Gly The See Arg Pro The 396
1425 CCG GTG GK TrC TCA GAA ACC AGA GGC CCA GM CTG ACC AG1 CIC CAT OCC ASO GCC CGA GhC CCT CAC AGC CTC TGG GTA GGC TOG GAG 1514
397 Pro Val Val Phe See Glu Sac Arq Gly Pro Ala Lwu The Arg Lau His Ala Hat Alt Arg Asp Pro His Sar Lou Trp V41 Gly Trp Glu 426Figure 1 D.
13.1%, respectively) and serine (13 and 10.4%) a property
noted for the cytoplasmic domains ofmany members of the
hematopoietin (HP) receptor family (44) . Neither the D7
nor 25-1 cytoplasmic regions contain sequences indicative of
tyrosine kinase activity (45) but Ser760 of the 25-1 receptor
represents a potential protein kinase C phosphorylation site
(46) . The predicted sequences of bothGCSF receptors con-
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x
U
U
U
O
2
12
4
C(x10 -9 )
Figure 2.
￿
Comparison of re-
combinant and native G-CSF
receptors. Binding assays described
in Material and Methods. (A)
Specific in situ binding of 1251-G-
CSF to COS cell-expressed re-
combinant G-CSF receptors 25-1
(O) and D7 (" ) for 2 h at 4°C .
Data plotted as bound (r) vs . free
ligand (C) . (B) Replotting A in
Scatchard coordinate system. linear
least squares analysis (30) yielded
similar ligand affinities for D7
(Kd = 1.6 nM ; n a 3.0 x 105)
and 25-1 (Kd = 0.53 nM; n =
5.2 x 104) ; but -6x higher ex-
pression levels of the former. (C)
Specific binding of 1251-GCSF to
nadve (placental membrane) GCSF
receptors. Linear least squares fit
to Scatchard plot give a Kd of
0.70 nM, similar to both recombinant receptors. (D) Affinity cross-linking ofnative (placental ; lanes 1 and 2) and recombinant (COS-expressed; lanes
3 and 4) in the absence (1 and 3) or presence (lanes 2 and 4) of a 200-fold molar excess of unlabeled G-CSF. The calculated receptor M after subtrac-
tion of ligand molecular weight, is -150,000 in both cases. Cross-linking conditions described in Materials and Methods .
0 20 40 60 80 100 120 140 160 180
r (fmoles/mg )
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tain nine potential --linked glycosylation sites (Fig. 1 B),
all but one in the proposed extracellular region . A murine
G-CSF receptor cDNA isolated from myeloid leukemia cell
library (25) encodes a predicted mature protein of 812 amino
acids, identical in length to that of 25-1, and its 000H-
termirial sequence is homologous to that of 25-1 but to D7
only up to the position of the proposed splice site. The 25-1
r (X10-5)cDNA appears, therefore, to encode the stricthumanhomo-
logue of the murine receptor. At the protein level, these homo-
logues are highly conserved in sequence (62% identity) .
Comparison of Native and Recombinant G-CSF Receptors.
The ligand-binding and affinity cross-linking characteris-
tics ofthe recombinant G-CSF receptors encoded byD7 and
25-1, expressed in COS cells, are compared with those of
native (placental) receptors in Fig. 2. All three receptors dis-
play a single class ofbinding sites, with equilibrium dissocia-
tion constants of 1.6 nM (D7), 0.53 nM (25-1), and 0.67
nM (placental) . Expression levels of the D7 clone, however,
were approximately sixfold higher than 25-1(298,000 v. 52,000
sites/cell) . Affinity cross-linking studies of COS-expressed
D7 and placental G-CSF receptors detected a single subunit
in each case with an apparent M, of -150,000 . As the cal-
culated protein molecular mass ofthe recombinant receptors
are 92 kD (25-1) and 86 kD (D7), the G-CSF receptor is
estimated to contain -35% carbohydrate by weight . Thus
both native and recombinant receptors share similar charac-
teristics.
Expression ofGCSFReceptormRNA.
￿
An antisense RNA
transcript of the entire D7 sequence was used to probe
Northern blots of total cellular RNAs isolated from a va-
riety of sources (Fig. 3) . A hybridizing band of-3 kb was
detected in placental RNA samples (lane 4) and RNA iso-
lated from human hematopoietic cells previously reported to
express G-CSF receptors (17, 22, 23, 47), including the my-
elogenous leukemia cell line KG-1 (Fig . 3, lane 7), the promye-
locytic cell line HIM (lane 1), the premonocytic cell line
U937 (lane 5), bone marrow cells (lane 7), and peripheral
blood granulocytes (lanes 2, 3), the latter containing partic-
ularly high levels, consistent with the prominent G-CSF re-
sponsiveness of this cell type. The KG-1 and peripheral blood
granulocyte samples both show a minor additional hybridizing
species at -7 kb (lanes 2, 3, and 7), as did placental RNA
upon longer exposure (data not shown) . This species was
not detectable in cytoplasmic placental RNA, suggesting it
is a nuclear precursor (data not shown) . The observed pat-
tern of expression suggests that one or both of the GCSF
receptors cloned from the placental library also encode the
receptors used by hematopoietic cells. Unexpectedly,we have
also detected low levels of these transcripts in the HTLV
1-transformedT cell lines C-10 and MJ (lanes 6,10) and the
B lymphoblastoid cell lines RAJI and RPMI 1788 (lanes 9,
11), cells that are of lymphoid not myeloid lineage. The
significance of this observation is unclear and requires fur-
ther investigation . Under the stringent hybridization condi-
tions used, no specific hybridization was seen with totalRNAs
isolated from HeLa cells (lane 8), dermal fibroblasts, brain,
or COS cells (data not shown) .
Domain Structure and Sequence Homology of the G-CSF
Receptor. A computer search of several databases queried with
the entire G-CSF receptor sequence revealed significant ho-
mology of the G-CSF receptor extracellular region to three
distinct groups of sequences : (a) members of the Ig super-
family (48), (b) the extracellular regions of all members of
the recently identified hematopoietin (HP) receptor family
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Figure3 .
￿
GCSFreceptorRNA analysis . Northern blotsof human total
cellular RNAs electrophoresed on formaldehyde agarose gels, hybridized
withantisense D7 probe, and washed as described in Materials andMethods.
The positions of the 18S and 28S ribosomal RNAs are indicated by arrows.
All lanes contain 2 .5 hg of total cellular RNA except lane 3, which has
0 .5 jug of total RNA to avoid overexposure. The blots were exposed at
minus 80° for different times. (A) 2-h exposure of ablot ofRNA samples
from the following sources : H1660 (lane 1), peripheralblood granulocytes
(lanes 2, 3), placenta (lane 4), U937 (lane 5) . (B) 24-h exposure ofa blot
ofRNAs isolated from the following sources : C-10 tlane 6), KG-1 (lane
7), HeLA (lane 8), RAJI (lane 9), MJ (lane 10), RPMI 1788 (lane 11),
aspirated pelvic bone marrow (lane 12).
(44, 49-53) and (c) the type III homology units (FN3) of
several vertebrate fibronectins (54) and neural cell adhesion
molecules (NCAMs) (55, 56) . Each of these homologies is
localized to discrete regions of the extracellular portion of
the G-CSF receptor. The NH2-terminal 90 residues of the
G-CSF receptor show statistically significant alignment scores
(>3 SD) with several members of the Ig superfamily (data
not shown) . Fig. 4A shows a consensus alignment of these
NH2-terminal residues with the NH2-terminal sequences
from the murine G-CSF receptor (25), human IIr6 receptor
(57), and light chain domains ofIgNEW (58, 59) . TheGCSF
receptor contains an invariant Trp, two appropriately spaced
Cys, and other residues in conserved positions that define
Ig-like domains (48) . Cys23 and Cys79 oftheGCSF receptor,
therefore, are likely to form a disulfide loop characteristic of
the Ig fold (60) . This structural motif is further supported
by the presence of sequences predicted to form theS strands
characteristic of Ig domains (underlined Fig. 4 A) .
The -200 residue segment of the G-CSF receptor fol-
lowing the Ig-like moiety (Arg94 to Pro 299) shows strong
homology to extracellular regions of all members of the HP
receptor family (ALIGN scores Fig. 4 D) (44) and is shown
aligned with the corresponding segments of the murine
receptor and other selected family members in Fig. 4, B and
C . This region contains the sequence features that define the
Cloning of a Human Granulocyte Colony-stimulating Factor ReceptorFigure 4.
￿
Homology domains of theGCSF
receptor .(A) Alignment ofthehumanandmu-
rlne GCSF receptor NH2-terminal Ig-like do-
main with thehuman 11,6 receptor Ig-like do-
main and the sequences from the light chains
ofIgNEW (58, 59) . Boldface type indicates
residues conserved in Ig domains . Underlined
ididice the acual residues involved resues nat
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fibronectin type III (FN3) domains of the
human and murine GCSF receptor extracellular region with the FN3-like domains of the HP receptor family defining regions (62) of the receptors
for 11,6, IL3, erythropoietin, and prolactin and with the five FN3 repeats ofmuriner .1 NCAM (55) the second FN3 repeat of Drosophila neuroglian
(63) and four type III repeats ofhuman fibronectin (64), Asterisks and shading indicate the three residuesconserved in all 16 repeats ofhuman fibronectin .
Shadingindicates otherresidues conserved in someFN3domainsand theWSXWS motifs. Cysand Trp residues are inboldface type. (D) Scores generated
by the NBRF ALIGN program (38) for the indicated sequences .
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hu1L4R 21 .6 17.2 19 .3 - 26.9 5.4 8.2 4.9 8.1 5.7 8.4 3.8 5,7 3.1 3.2HP receptor family; notably a Trp and four Cys residues (boxes,
asterisks: Fig. 4 B) conforming to a conserved pattern (49-53)
found in nearly all HP receptors (44) and a COON-terminal
WSXWS motif (50-53) which has proven to be a hallmark
of the HP receptor family (44). The four Cys residues form
two successive disulfide loops in the growth hormone receptor
(61), and it is likely that a similar pairing occurs in the GCSF
receptor between Cys107 and 118, and Cys153 and 162. A
recent sequence analysis of the HP receptor family-defining
region (62) has suggested it can be resolved into two distinct
elements each -100 residues in length: one NH2-terminal
"cysteine-rich" region and a COON-terminal "rysteine-poor"
region, the latter homologous to fibronectin type III repeats.
Although in the G-CSF receptor these two regions do not
differ significantly in number of Cys residues (NH2-ter-
minal, 6; COOH-terminal, 5), the last 100 residues of the
region do contain the sequence features characteristic ofFN3
repeats, as shown by alignment with examples of FN3 repeats
from human fibronectin (54) and two neural cell adhesion
molecules, murine Ll (55) and Drosophila neuroglian (63)
in Fig. 4 C. The FN3-like character of the region is demon-
strated by the presence of three residues, Trp229, Leu274,
and Tyr279 (asterisks), in the pattern which is the sole se-
quence feature absolutely conserved in all of the type III repeats
of fibronectin (54, 64). Although this region of the G-CSF
receptor exceeds the low Trp and Cys content characteristic
of FN3 repeats (54) its designation as an FN3-like domain
is further supported by statistically significant ALIGN scores
when compared with 14 of the 16 type III repeats of human
fibronectin (data not shown).
The -300 residues of the G-CSF receptor bordered by the
WSXWS motif and the transmembrane region also show
significant homology to FN3 repeats of several vertebrate
fibronectins and NCAMs, suggesting this region consists of
three additional repeats o£ this element. These proposed FN3-
like domains are shown aligned with the corresponding seg-
ments of the murine receptor and the examples ofFN3 repeats
in Fig. 4 C. These three FN3-like domains of the G-CSF
receptor contain the conserved Trp and Tyr residues, described
above, but only the last domain contains the hallmark Leu,
a residue only partially conserved in NCAM FN3 repeats.
These domains of the G-CSF receptor also contain a pair of
aromatic residues common to the FN3-like domains of many
NCAMs and fibronectins (boxed). The four proposed FN3-
like domains of the G-CSF receptor each contain at least three
Trp residues, and in this respect resemble the FN3 repeats
of NCAMs rather than those of fibronectin. The proposed
second, third, and fourth FN3 domains of the GCSF receptor
gave significant ALIGN scores respectively to 4, 13, and 15,
of the 16 type III repeats of human fibronectin (data not
shown).
Discussion
Here we report the isolation and characterization of two
distinct types of G-CSF receptor cDNAs from a human
placental library. The equilibrium ligand binding and cross-
linking characteristics of the recombinant receptors are similar
to those of native receptors on placental membranes (Fig. 2).
The D7 and 25-1 cDNAs are predicted to encode integral
membrane glycoproteins, 759 and 812 amino acids in mature
length, respectively. The predicted molecular masses of these
receptors, 86 and 92 kD, are substantially less than the -150
kD inferred by affinity crosslinking, suggesting that some
or all of the nine potential Winked glycosylation sites con-
tain carbohydrate. The two receptors share identical extracel-
lular (603 aa) and transmembrane (26 aa) regions, as well as
the first 96 residues in their cytoplasmic regions, but have
alternate COON-terminal sequences of34 residues (D7) and
87 residues (25-1). The nucleotide sequences of the two cDNAs
indicate that they are probably derived from alternatively
processed transcripts ofthe same gene, since they differ only
with respect to a 419-bp insert in the 25-1 cDNA that ap-
pears to be an unspliced intron. A recently reported murine
G-CSF receptor cDNA (25) encodes a protein that shows
strong homology to both placental G-CSF receptors up to
the splice point in the cytoplasmic domain, after which the
homology continues only in the 25-1 clone, indicating it is
the strict human homologue of the reported murine receptor.
It is unclear if the reported murine G-CSF receptor cDNA
sequence has the splicing potential to encode an alternate
COON-terminus. Inspection ofthe murine sequence reveals
a very similar (murine, CAG GTCCTC; human, CAG
GTCCTT) potential splice donor sequence located within
the same DQ/VLY peptide sequence as the human 25-1
cDNA. However, while there are potential splice acceptor
sites in the murine sequence, translation of the sequences
downstream in all three reading frames reveal no significant
homology to the D7 type COOH terminus. Thus, genera-
tion of a D7-type cytoplasmic terminus in murine G-CSF
receptors might be possible if an alternative splice acceptor
site exists in 3' sequences of the murine gene.
Differential splicing results in the tissue-specific expression
of transcripts encoding alternate cytoplasmic domains for at
least two other cell surface proteins, rat liver prolactin (PRL)
receptor (65) and chicken NCAM (66). The tissue specificity
of expression of the potential G-CSF receptor isoforms re-
mains to be determined at both the mRNA and protein level,
but a preliminary analysis with specific oligonucleotide probes
suggests humangranulocytes express predominantly transcripts
of the 25-1 type (data not shown). This raises the possibility
that the D7 receptor is specifically expressed at higher levels
in nonhematopoietic cellssuch as placenta, and suggests that
the alternate cytoplasmic domains may confer functional differ-
ences to the two receptors. It hasbeen proposed that the smaller
form ofthe PRL receptor functions in ligand transport across
epithelialbarriers in liver rather than in signal transduction
(65). By analogy the D7 isoform of the G-CSF receptor may
serve to transport or sequester G-CSF in placental tissues.
Alternatively, the two isoforms may differ in signal trans-
duction properties, reflecting in part, the diverse biological
effects of G-CSF. While the signal transduction mechanism
of the G-CSF receptor is unclear, it is interesting that the
25-1 receptor, unlike D7, does contain one potential C ki-
nase phosphorylation site (46). Signal transduction may also
be effected through a distinct subunit with which the ligand-
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IIr6 receptor system (67). Conceivably, this subunit may be
gp130 itself, and it is interesting, in this regard, that IIr6
and G-CSF show significant sequence homology (68), and
theirreceptors share a similar domain composition (see below).
Both G-CSF receptor cytoplasmic domains contain a high
proportion of Pro and Ser residues, like those of many other
HP receptor family members (44), the significance of which
remains to be elucidated. The cytoplasmic sequence of these
receptors may influence stability, cellular localization, or as-
sociation with other membrane proteins.
The extracellular region of the G-CSF receptor consists
of three distinct regions of homology to other cell surface
proteins: (a) a -90 residue NHz-terminal Ig-like region, (b)
a -200 residue HP receptor superfamily-definingregion, and
(c) -300 residues of three tandem FN3-like repeats. Consis-
tent with the proposal of Patthy (62), the COOH-terminal
100 residue segment of the HP receptor family-defining re-
gion of the G-CSF receptor appears to be an FN3-like do-
main, albeit one with an elevated Trp and Cys content that
is unique among FN3 repeats. Since many protein domains
are -100 residues in length, it is likely that the NHz-ter-
minal"cysteine-rich" or double-loop region ofthe HP receptor-
defining region is, like the WSXWS-containing FN3 element,
a discrete structural domain. Thus, the structure ofthe GCSF
receptor extracellular region can be resolved into the 6 do-
mains of -100 residues each shown schematically in Fig. 5.
By this analysis, the G-CSF receptor appears to be a mosaic
of four types of domains, two found associated only in HP
receptors (double-loop and WSXWS-FN3) and two found
together in NCAMs (NHz-terminal Ig and membrane-
proximal FN3s). Given the likelihood that the Ig superfamily
molecules of the immune system arose from NCAM-like an-
cestors (48), it is tempting to speculate that the GCSF receptor
retains the domain structure of an early intermediate in the
evolution of the HP receptor superfamily from these same
ancestors. Successive deletion ofthe terminal extracellular do-
mains of a G-CSF receptor-like molecule could thus yield
all known HP receptor domain structures; deletion of the
three FN3 domains yields an 11,6 receptor-like structure, and
further deletion of the Ig domain leads to the core domain
structure of most HP receptors, which is duplicated in the
case of the IIr3 receptor. Key to such a proposal is determina-
tion ofthe origin ofthe cysteine-rich or double-loop domain,
thus far a unique domain feature found only in the HP
receptors, but which, like the Ig and FN3 domains, may also
have arisen from a domain in some NCAM-like ancestor.
The function of these structural domains in the G-CSF
receptor is unclear. The HP receptor family-defining region,
which comprises the entire extracellular region of many of
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Figure 5.
￿
Schematic representation of the nominal structure ofhema-
topoietin receptors and a typical neural cell adhesion molecule. Ig-like do-
mains are shown as large loops. FN3 domains are shown as rectangular
boxes. The cysteine-rich, double-loop domains of HP receptor family-
defining regions are shown as a pair ofsmallloops, to represent the disulfide
pairing determined for human growth hormone receptor (61). The FN-3
like domain of HP receptor family-defining regions is designated as a
rectangular box crossed by a heavy bar representing the WSXWS motif.
Sequences represented are rat NCAM (reference 79 as drawn in 56), IL6
receptor (57), and 11,3 receptor (53).
these receptors, presumably contains the ligand binding site
of the G-CSF receptor. The Ig and extra FN3-like domains
of the GCSF receptor may confer additional activities to this
receptor, similar to the complex functions recognized for these
domains in other cell surface molecules. These generally ap-
pear to involve participation in some form o£cell recognition
or adhesion. Both types of domains are capable of homo-
typic and heterotypic interactions (48, 69) that might lead
to receptor self-association or binding to other proteins. Specific
functions have been attributed to some type III repeats of
fibronectin, including the binding of cells and heparin (70,
71) and heparin binding activity is also a property ofat least
one neural cell adhesion molecule (72). The potential for simul-
taneous recognition of heparin and G-CSF by the G-CSF
receptor would have interesting functional implications, es-
pecially in light of the affinity of the heparin component of
extracellular matrix for CSFs (73, 74). The particularresponse
of a cell to G-CSF could thus depend on its adherence or
that of G-CSF to the extracellular matrix. Alternatively it
could allow GCSF to mediate or specify interactionsbetween
cells and matrix, thus, directing margination or chemotaxis.
The cloning of the human G-CSF receptor will provide re-
agents useful in the father elucidation ofthe biological roles
of G-CSF and may allow development of new diagnostic or
therapeutic agents.
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